Business Segments · Reclassification to: cost of sales
Orthopaedics — Reclassification to: cost of sales
Stryker Orthopaedics — Reclassification to: cost of sales decreased by 62.8% to $823M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 61.2%, from $2.12B to $823M. This is a positive signal — lower values indicate better performance for this metric.
Analysis
StatementSegment
CategoryProfitability
SignalLower is better
VolatilityStable
First reportedQ1 2016
Last reportedQ1 2026May 11, 2026
Rolls up toTotal Cost of Revenue
How to read this metric
An increase suggests a shift in how the company accounts for production-related costs, potentially impacting reported gross margins.
Detailed definition
This represents specific costs previously categorized elsewhere that have been reclassified into the cost of goods sold...
Peer comparison
Similar to cost reclassifications or accounting adjustments found in the segment reporting of other medical device manufacturers.
Metric ID:
syk_segment_orthopaedics_reclassification_to_cost_of_salesHistorical Data
37 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q1 '22 | Q2 '22 | Q2 '22 | Q3 '22 | Q3 '22 | Q4 '22 | Q4 '22 | Q1 '23 | Q1 '23 | Q2 '23 | Q2 '23 | Q3 '23 | Q3 '23 | Q4 '23 | Q4 '23 | Q1 '24 | Q1 '24 | Q2 '24 | Q2 '24 | Q3 '24 | Q3 '24 | Q4 '24 | Q4 '24 | Q1 '25 | Q1 '25 | Q2 '25 | Q2 '25 | Q3 '25 | Q3 '25 | Q4 '25 | Q4 '25 | Q1 '26 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.52B | $1.52B | $1.66B | $1.54B | $480M | $1.67B | $480M | $1.7B | $480M | $1.97B | $480M | $1.76B | $563.5M | $1.82B | $563.5M | $1.75B | $563.5M | $2.11B | $563.5M | $1.91B | $591M | $2.01B | $576M | $1.98B | $561M | $2.26B | $672M | $2.12B | $775M | $2.18B | $599M | $2.21B | $620M | $2.54B | $722M | $2.21B | $823M |
| QoQ Change | — | -0.3% | +9.1% | -6.9% | -68.9% | +247.3% | -71.2% | +253.5% | -71.7% | +309.6% | -75.6% | +267.1% | -68.0% | +222.1% | -69.0% | +210.7% | -67.8% | +274.8% | -73.3% | +239.0% | -69.1% | +239.4% | -71.3% | +243.2% | -71.6% | +303.2% | -70.3% | +215.8% | -63.5% | +181.4% | -72.5% | +268.1% | -71.9% | +310.2% | -71.6% | +206.1% | -62.8% |
| YoY Change | — | — | — | — | — | +9.5% | -68.5% | +11.8% | -68.4% | +18.7% | -71.0% | +14.3% | -63.4% | +8.9% | -66.2% | +3.2% | -66.8% | +7.4% | -71.3% | +8.4% | -66.5% | +10.5% | -68.3% | +12.9% | -68.0% | +7.1% | -68.2% | +11.1% | -59.4% | +8.7% | -70.1% | +11.5% | -68.6% | +12.4% | -68.1% | +4.1% | -61.2% |
Range$480M – $2.54B
CAGR-6.6%
Avg YoY Growth-28.5%
Median YoY Growth-28.1%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Stryker's orthopaedics — reclassification to: cost of sales?
- Stryker (SYK) reported orthopaedics — reclassification to: cost of sales of $823M in Q1 2026.
- How has Stryker's orthopaedics — reclassification to: cost of sales changed year-over-year?
- Stryker's orthopaedics — reclassification to: cost of sales decreased by 61.2% year-over-year, from $2.12B to $823M.
- What does orthopaedics — reclassification to: cost of sales mean?
- Adjustments that move expenses into the direct cost of producing orthopedic goods.